Abstract
Hepatitis C virus (HCV) accounts for the majority of cases of transfusion acquired hepatitis and hepatitis transmitted by injecting drug use. The patients who do not clear the infection become chronic carriers of HCV and form a reservoir of infection within human populations. Furthermore, these carriers are at serious risk of developing cirrhosis of the liver and hepatocellular carcinoma. The disease is of major concern in developing as well as in developed countries and yet there are no vaccines against HCV, treatment is confined to the use of chemotherapy which is expensive and not always effective. The major obstacle in vaccine development is a limited understanding of the type of immune response that is necessary for viral clearance and the occurrence of various genotypes and quasispecies of HCV. The problems are further compounded by difficulties in growing the virus in vitro and the lack of a suitable and economical animal model. In this review we describe the virus, the strategies that it uses to evade the immune response and the tactics that may be useful in designing successful vaccine candidates.
Keywords: Hepatitis, immune response, quasispecies, chemotherapy
Current Drug Targets
Title: Neutralising Antibody, CTL and Dendritic Cell Responses to Hepatitis C Virus: A Preventative Vaccine Strategy
Volume: 5 Issue: 1
Author(s): Joseph Torresi, Mandvi Bharadwaj, David C. Jackson and Eric J. Gowans
Affiliation:
Keywords: Hepatitis, immune response, quasispecies, chemotherapy
Abstract: Hepatitis C virus (HCV) accounts for the majority of cases of transfusion acquired hepatitis and hepatitis transmitted by injecting drug use. The patients who do not clear the infection become chronic carriers of HCV and form a reservoir of infection within human populations. Furthermore, these carriers are at serious risk of developing cirrhosis of the liver and hepatocellular carcinoma. The disease is of major concern in developing as well as in developed countries and yet there are no vaccines against HCV, treatment is confined to the use of chemotherapy which is expensive and not always effective. The major obstacle in vaccine development is a limited understanding of the type of immune response that is necessary for viral clearance and the occurrence of various genotypes and quasispecies of HCV. The problems are further compounded by difficulties in growing the virus in vitro and the lack of a suitable and economical animal model. In this review we describe the virus, the strategies that it uses to evade the immune response and the tactics that may be useful in designing successful vaccine candidates.
Export Options
About this article
Cite this article as:
Torresi Joseph, Bharadwaj Mandvi, Jackson C. David and Gowans J. Eric, Neutralising Antibody, CTL and Dendritic Cell Responses to Hepatitis C Virus: A Preventative Vaccine Strategy, Current Drug Targets 2004; 5 (1) . https://dx.doi.org/10.2174/1389450043490677
DOI https://dx.doi.org/10.2174/1389450043490677 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stereotactic Body Radiation Therapy in Head and Neck Squamous Cell Carcinoma: Science or Art?
Current Cancer Therapy Reviews A Comprehensive Review on Nanotechnology-Based Innovations in Topical Drug Delivery for the Treatment of Skin Cancer
Current Pharmaceutical Design Hybrid PET Imaging in Neurologic Disease: PET/MRI Rather than PET/CT
Current Medical Imaging Editorial [Hot Topic: Why Apoptosis in Pediatric Disorders?]
Current Pediatric Reviews Synthetic Molecules that Modulate Transcription and Differentiation: Hints for Future Drug Discovery
Combinatorial Chemistry & High Throughput Screening State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Current Medicinal Chemistry Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas
Current Cancer Drug Targets Lessons from Viruses: Controlling the Function of Transmembrane Proteins by Interfering Transmembrane Helices
Current Medicinal Chemistry The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets β -[<sup>18</sup>F]Fluoro Azomycin Arabinoside (β -[<sup>18</sup>F]FAZA): Synthesis, Radiofluorination and Preliminary PET Imaging of Murine A431 Tumors
Current Radiopharmaceuticals Perineural Invasion in Adenoid Cystic Carcinoma of the Salivary Glands: Anatomical Influences on Oncological Management
Current Cancer Therapy Reviews Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Current Medicinal Chemistry Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry New Non-Nucleocide NS5B Protein Inhibitors for the Treatment of Chronic Hepatitis C Infection
Current Topics in Medicinal Chemistry The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Signalling Pathways Activated by Ultraviolet Radiation: Role in Ocular and Cutaneous Health
Current Pharmaceutical Design